Internal Reference Number: FOI_6580
Date Request Received: 05/05/2022 00:00:00
Date Request Replied To: 24/05/2022 00:00:00
This response was sent via: By Email
Request Summary: Biologic and biosimilar products within Rheumatology
Request Category: Companies
| Question Number 1: Please provide the numbers of patients treated by the Rheumatology department (for any condition) in the last 3 months with the following drugs: 鈥� Abatacept [Orencia] 鈥� Adalimumab [Humira] 鈥� Adalimumab Biosimilars 鈥� Apremilast [Otezla] 鈥� Baricitinib [Olumiant] 鈥� Certolizumab [Cimzia] 鈥� Etanercept [Enbrel] 鈥� Etanercept Biosimilars 鈥� Filgotinib [Jyseleca] 鈥� Golimumab [Simponi] 鈥� Guselkumab [Tremfya] 鈥� Infliximab [Remicade] 鈥� Infliximab Biosimilars 鈥� Ixekizumab [Taltz] 鈥� Risankizumab [Skyrizi] 鈥� Rituximab [MabThera] 鈥� Rituximab Biosimilars 鈥� Sarilumab [Kevzara] 鈥� Secukinumab [Cosentyx] 鈥� Tocilizumab [Ro Actemra] 鈥� Tofacitinib [Xeljanz] 鈥� Upadacitinib [Rinvoq] 鈥� Ustekinumab [Stelara] | |
| Answer To Question 1: abatacept 47 adalimumab (Humira) 27 adalimumab (biosimilars) 231 apremilast 5 baricitinib 72 certolizumab 41 etanercept (Enbrel) 10 etanercept (biosimilars) 112 filgotinib 21 golimumab 22 guselkumab <5 infliximab (Remicade) 8 infliximab (biosimilars) 27 ixekizumab 27 risankizumab 0 rituximab (Mabthera) 0 rituximab (biosimilars) 21 sarilumab <5 secukinumab 18 tocilizumab 48 tofacitinib 31 upadacitinub 31 ustekinumab 8 | |
| To return to the list of all the FOI requests please click here |
Our staff at Salisbury District Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of 看片软件 Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.
